Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
=============================================================================================================================================================================

* M. Fishman
* J. P. Dutcher
* J. I. Clark
* A. Alva
* G. P. Miletello
* B. Curti
* Neeraj Agarwal
* R. Hauke
* K. M. Mahoney
* H. Moon
* J. Treisman
* S. S. Tykodi
* G. Daniels
* M. A. Morse
* M. K. K. Wong
* H. Kaufman
* N. Gregory
* D. F. McDermott